OverviewSuggest Edit

Calviri is a company that develops diagnostic and therapeutic products, as well as vaccines aimed to prevent cancer. Its approach is based on the discovery of an unrecognized source of frameshift neoantigens. These immunogenic peptides are generated from frequent errors in tumor-cell RNA synthesis and processing. They provide both cancer-specific and shared frameshift neoantigens for a new class of diagnostic and vaccine products.

Latest Updates

Employees (est.) (Oct 2020)5
Cybersecurity ratingAMore

Calviri Financials and Metrics

Summary Metrics

Founding Date


Calviri total Funding

$2.3 m

Calviri latest funding size

$2.25 m

Time since last funding

7 months ago

Calviri investors

Calviri's latest funding round in April 2020 was reported to be $2.3 m. In total, Calviri has raised $2.3 m
Show all financial metrics

Calviri Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Calviri Online and Social Media Presence

Embed Graph

Calviri Frequently Asked Questions

  • When was Calviri founded?

    Calviri was founded in 2018.

  • How many employees does Calviri have?

    Calviri has 5 employees.

  • Who are Calviri competitors?

    Competitors of Calviri include Cellectar Biosciences, Isotopen Technologien Munchen and A&G Pharmaceutical.